Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans.
OBJECTIVE
To evaluate the effect of sarpogrelate for patients with atherosclerotic obliterans (ASO).


METHODS
Patients with ASO were randomly divided into sarpogrelate group (n = 92) and control group (n = 84). The patients in sarpogrelate group received sarpogrelate (100 mg, tid), whereas in control group aspirin (100 mg, qd) was administered orally. The patients were followed up monthly to observe any side effect of medication. Clinical manifestation, painless walking distance, Rutherford type and ankle brachial Index (ABI) were studied.


RESULTS
In comparison with control group, the severity of pain, Rutherford type 0 and 1 were improved with statistic significance. Incidence of patients with intermittent claudication decreased from 56.6% before treatment to 28.3% after treatment; the painless walking distance was prolonged (116.3 ± 72.3m vs. 243.5 ± 175.3m, P <0.001); ABI values were increased (0.74 ± 0.17 vs. 0.86 ± 0.18; p <0.001). No side effect of medication was observed.


CONCLUSIONS
Sarpogrelate has a therapeutic effect on patients with atherosclerotic obliterans.
Cardiovascular Surgery, China-Japan Friendship Hospital, the Chinese Ministry of Health, Beijing, China.
Shiyan
S
Ren
Songyi
S
Qian
Wei
W
Wang
Jiagtao
J
Liu
Peng
P
Liu
D000368:Aged; D055109:Ankle Brachial Index; D001162:Arteriosclerosis Obliterans / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002681:China; D005080:Exercise Test; D017079:Exercise Tolerance; D005260:Female; D006439:Hemodynamics; D006801:Humans; D007383:Intermittent Claudication / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D011237:Predictive Value of Tests; D011446:Prospective Studies; D020127:Recovery of Function; D012720:Severity of Illness Index; D013386:Succinates / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D016138:Walking
D002317:Cardiovascular Agents; D013386:Succinates; C064294:sarpogrelate